grant
Overcoming Resistance to Targeted Therapy in Breast Cancer
Organization SLOAN-KETTERING INST CAN RESEARCHLocation NEW YORK, UNITED STATESPosted 20 Aug 2025Deadline 31 Jul 2032
NIHUS FederalResearch GrantFY20251-Phosphatidylinositol 3-KinaseAntibodiesAntibody-drug conjugatesAntioncogene Protein p53Automobile DrivingBiological MarkersBreast CancerBreast Cancer ModelBreast OncologyBreast tumor modelCDK4CDK4 geneCause of DeathCell Division Kinase 4Cellular Tumor Antigen P53ClinicClinicalCyclin-Dependent Kinase 4DNA AlterationDNA Sequence AlterationDNA mutationDiseaseDisorderDrug TargetingDrug resistanceERBB2ERBB2 geneERalphaERαESR1ESR1 geneEndocrineEstradiol Receptor alphaEstradiol Receptor αEstrogen Receptor 1Estrogen Receptor alphaEstrogen Receptor αGenerationsGenetic AlterationGenetic ChangeGenetic defectGenetic mutationGenetics-MutagenesisGenome InstabilityGenomic InstabilityGenomicsGoalsHER -2HER-2HER2HER2 GenesHER2/neuLinkMMAC1MMAC1 proteinMalignant Breast NeoplasmMalignant CellMetastatic breast cancerModelingModernizationMutagenesisMutagenesis Molecular BiologyMutated in Multiple Advanced Cancers 1MutationNEU OncogeneNEU proteinNR3A1Oncogene ErbB2Oncogene ProductsOncogene ProteinsOncoprotein p53OncoproteinsOralOutcomeP53PHTS genePHTS proteinPI-3 KinasePI3-KinasePI3CGPI3KGammaPI3kPIK3PIK3CGPIK3CG genePSK-J3PTENPTEN genePTEN proteinPTEN1Pathway interactionsPatientsPharmacologyPhasePhosphatase and Tensin HomologPhosphatase and Tensin Homolog Deleted on Chromosome 10Phosphatidylinositol 3-KinasePhosphatidylinositol-3-OH KinasePhosphoinositide 3-HydroxykinasePhosphoprotein P53Phosphoprotein pp53ProcessProtein TP53PtdIns 3-KinaseResearchResistanceResistance developmentResistant developmentSamplingSequence AlterationTKR1TP53TP53 geneTRP53Tumor Protein p53Tumor Protein p53 GeneType I Phosphatidylinositol KinaseType III Phosphoinositide 3-KinaseUnited StatesWomen's mortalityadvanced breast canceradvanced stage breast cancerbio-markersbiologic markerbiomarkerc-erbB-2c-erbB-2 Genesc-erbB-2 Proto-Oncogenescancer cellcohortdeath among femalesdeath among womendeath in femalesdeath in womendeath rate among womendeath rate in womendeveloping resistancedisease controldisorder controldrivingdrug resistanterbB-2 Genesfemale deathfemale mortalitygenome mutationgenomic alterationherstatinhomologous recombination deficiencyhomologous recombination repair deficiencyimprovedinhibitorinsightmalignant breast tumormammary cancer modelmammary tumor modelmetastatic breast tumormetastatic mammary cancermetastatic mammary tumormortalitymortality among femalesmortality among womenmortality in femalesmortality in womenmutated in multiple advanced cancers 1 proteinneu Genesnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyp53 Antigenp53 Genesp53 Tumor Suppressorpathwaypharmacologicphosphatase and tensin homologue on chromosome tenprotein p53resistance mechanismresistance to Drugresistance to therapyresistantresistant mechanismresistant to Drugresistant to therapyresponsetargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapy resistanttreatment resistancewomen's deathwomen's death rate
Description preview
PROJECT SUMMARY
Therapies directed against lineage and oncoprotein drivers in breast cancer have led to major improvements in
clinical outcomes, establishing the significance of these drug targets. In metastatic breast cancer, eventual
resistance to these drugs is unfortunately common and represents a major clinical dilemma. We have focused
our…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click